Statement: neither the primary clinical trial nor the secondary clinical trial keep a record of adverse events related to cardiac or infection issues, however they both have noted several occurrences of epilepsy
Primary_evidence: Adverse Events 1:   Total: 0/655 (0.00%) Adverse Events 2:   Total: 0/580 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 0/15 (0.00%) Adverse Events 2:   Total: 0/16 (0.00%)